Draft:EUPROTEIN Inc.

Bio-Techne Announces Release of a New SARS-CoV-1/2 Spike RBD LlaMABody™ Recombinant Antibody that Blocks Viral Entry

Retrieved on: 
Tuesday, August 11, 2020
Sarbecovirus, Medical specialties, Zoonoses, Branches of biology, Animal diseases, COVID-19, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome coronavirus, Antibody, Severe acute respiratory syndrome–related coronavirus, Draft:EUPROTEIN Inc.

MINNEAPOLIS, Aug. 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds to the SARS-CoV-2 spike receptor binding domain (RBD) and blocks the virus from binding to its host receptor, ACE-2, inhibiting viral infection .

Key Points: 
  • MINNEAPOLIS, Aug. 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds to the SARS-CoV-2 spike receptor binding domain (RBD) and blocks the virus from binding to its host receptor, ACE-2, inhibiting viral infection .
  • The SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody is the first camelid antibody offering in our new LlaMABody product line.
  • This antibody reflects Bio-Techne's well-established expertise in recombinant antibody engineering as a growing segment in our business, especially in biopharma.
  • "This new SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody is just part of a growing portfolio of tools from Bio-Techne that support SARS-CoV-2 research, diagnostics and therapeutic development."